Compare VRAX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | PAVM |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | 107 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 8.7M |
| IPO Year | 2021 | N/A |
| Metric | VRAX | PAVM |
|---|---|---|
| Price | $0.20 | $10.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $510.00 |
| AVG Volume (30 Days) | ★ 188.3K | 65.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | $450.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.21 |
| 52 Week High | $1.58 | $28.44 |
| Indicator | VRAX | PAVM |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 60.16 |
| Support Level | $0.20 | $0.39 |
| Resistance Level | $0.25 | $12.50 |
| Average True Range (ATR) | 0.02 | 0.92 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 33.10 | 79.53 |
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.